Becton, Dickinson and Company - Enterprise Tech Ecosystem Series

Becton, Dickinson and Company - Enterprise Tech Ecosystem Series

Summary

Becton Dickinson and Co (BD) is a medical technology company, which manufactures and sells medical devices, reagents, and instruments. Its major products include syringes and pen needles; intravenous catheters; infusion pumps and disposables; automated medication dispensing and supply management systems; pre-fillable drug delivery systems; respiratory ventilation and diagnostic equipment and consumables; products for the safe collection and transportation of diagnostic specimens; instruments and reagent systems to detect a range of infectious diseases and cancers; and clinical research tools. BD offers its products for life science researchers, healthcare institutions, clinical laboratories, pharmaceutical industry and general public. The company sells its products in the Americas, Europe, the Middle East, Africa, and Asia-Pacific.

BDTI is an R&D unit of Becton Dickinson located at Research Triangle Park in North Carolina. It is responsible for identification and development of next generation technological solutions aligned with the company’s strategy.

Established in 2017, BD Research Centre Ireland facility focuses on product and software development, clinical research instrumentation and prototype development for company’s Life Sciences segment.

In May 2014, BD partnered with Microsoft to launch an accelerator in Israel for identifying and supporting potential healthcare start-ups providing advanced medical solutions.

The report provides information and insights into Becton, Dickinson and Company's tech activities, including -

• Insights of its digital transformation strategies and innovation programs
• Overview of technology initiatives covering partnerships, product launches, investments and acquisitions
• Insights on each technology initiative including technology theme, objective, and benefits
• Details of estimated ICT budgets and major ICT contracts

Scope

• In 2021, BD introduced BD Veritor at-home COVID-19 test solution by leveraging computer vision technology in a smartphone to interpret testing results. Some of its in-house technology solutions include BD Kiestra lab automation solutions; BD Synapsys Informatics; and BD Analytics.
• BD also provides various cytology instruments including BD Totalys System and BD PreMate to reduce inefficiencies related to cervical cancer screening procedures and automate specimen transfer solutions.
• BD has partnered with Microsoft for various technological solutions. The partnership enables the company to leverage machine learning algorithms that automate its manual review procedures by corroborating patients’ electronic medical records and device performance data.
• In November 2021, BD appointed Dr. Joseph M. Smith as senior vice president and chief scientific officer, responsible for external innovation and BD's technology roadmap to deliver transformative innovations. Smith will lead a reinvigorated focus on external technology partnerships and oversee the development of innovation models.

Reasons to Buy

• Gain insights into BD's tech operations.
• Gain insights into its tech strategies and innovation initiatives.
• Gain insights into its technology themes under focus.
• Gain insights into various product launches, partnerships, investments and acquisition strategies.